YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Earnings Call Insights: Veru Inc. (VERU) Q3 fiscal 2026 MANAGEMENT VIEW * Dr. Mitchell Steiner said Veru is focused on two small molecules, with near-term emphasis on enobosarm in obesity: enobosarm is being developed “as a next-generation…
Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar…
Major earnings expected before the bell on Monday include: * Barrick Mining Corporation (B [https://seekingalpha.com/symbol/B]) * Medical Properties Trust (MPT [https://seekingalpha.com/symbol/MPT]) * Seadrill Limited (SDRL [https://seekin…
(RTTNews) - Veru Inc. (VERU), a late clinical-stage biopharmaceutical company, on Monday announced full enrollment in the Phase 2b Plateau study evaluating oral Enobosarm with Semaglutide in older adults with obesity. The study will assess…
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage b…
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announc…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) has signed a clinical supply agreement with Veru Inc. to provide Wegov…
(RTTNews) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business; Absci, ahead of clinical trial readouts; and Alvotech…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027— --Company to host conference call and webcast today at 8:00 a.m. ET— MIAMI, FL,…
[Rolled newspaper with the headline Quarterly Results] Zerbor As earnings season enters another busy stretch, the upcoming week will bring a diverse mix of reports spanning AI infrastructure, semiconductors, e-commerce, clean energy, crypt…
-- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide --…
-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb.…
Major earnings expected before the bell on Wednesday include: * Shopify (SHOP [https://seekingalpha.com/symbol/SHOP]) * McDonald's Corporation (MCD [https://seekingalpha.com/symbol/MCD]) * The Kraft Heinz Company (KHC [https://seekingalpha…
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announc…
Major earnings expected before the bell on Wednesday include: * General Mills (GIS [https://seekingalpha.com/symbol/GIS]) * Jabil (JBL [https://seekingalpha.com/symbol/JBL]) * Veru (VERU [https://seekingalpha.com/symbol/VERU]) * The Toro C…
[Business.] artisteer/iStock via Getty Images The upcoming week may be a quiet one for earnings reports, but several notable companies are poised to grab investor attention. Tech stalwart BlackBerry (BB [https://seekingalpha.com/symbol/BB]…
[Blue line with cogs and numbers] Jonathan Kitchen/DigitalVision via Getty Images U.S. markets were coming off the Thanksgiving holiday and will operate on a shorter schedule on Friday, closing at 1 p.m. ET for Black Friday. After the Than…
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced tod…
Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shar…
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announ…
Veru Inc. VERU recently announced the selection of a novel modified-release oral formulation for enobosarm for chronic weight loss management. Enobosarm is a selective androgen receptor modulator (SARM) being developed as a next-generation…
Earnings Call Insights: Veru Inc. (VERU) Q3 2025 MANAGEMENT VIEW * CEO Mitchell S. Steiner reported that Veru is focusing its late clinical-stage biopharmaceutical efforts on cardiometabolic and inflammatory diseases, emphasizing two clini…
* Veru press release [https://seekingalpha.com/pr/20197066-veru-reports-fiscal-2025-third-quarter-financial-results-and-clinical-program-progress] (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]): Q3 GAAP EPS of -$0.50 beats by $0.03.…
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-…
Major earnings expected before the bell on Tuesday include: * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * Cardinal Health (CAH [https://seekingalpha.com/symbol/CAH]) * Circle Internet Group (CRCL [https://seekingalpha.com/symbo…
* Veru (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]) is scheduled to announce Q3 earnings results on Tuesday, August 12th, before market open. * The consensus EPS Estimate is -$0.50 [https://seekingalpha.com/symbol/VERU/earnings/est…
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced s…
* Veru (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]) on Wednesday announced a reverse stock split at a ratio of 1-for-10, effective August 11, 2025. * At the effective time, all outstanding stock options, stock appreciation rights,…
MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announc…
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced i…
MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announc…
When InvestingPro’s Fair Value models identified (NASDAQ:VERU) as significantly undervalued in January 2024, the healthcare company’s stock was trading at just $0.41. Today, that analysis has proven remarkably accurate, with shares deliver…
Over the last 7 days, the United States market has risen by 1.7%, and over the past year, it is up 12%, with earnings forecasted to grow by 15% annually. For investors seeking opportunities beyond well-known stocks, penny stocks can offer…
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly…
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announc…